Advancing Abbott's Long-term Strategy

Separating into Two Leading Companies in Diversified Medical Products and Research-Based Pharmaceuticals

October 21, 2011

Abbott
A Promise for Life

Forward-Looking Statement

Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995, including the planned separation of the research-based pharmaceutical company from the diversified medical products company and the expected financial results of the two companies after the separation. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward looking statements, and there is no assurance as to the timing of the planned separation or whether it will be completed. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2010 and in the interim reports filed on Form 10-Q for subsequent quarterly periods, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.

Agenda

9:00 - 9:45 a.m.	• Strategic Rationale • Overview of Abbott Diversified Medical Products Company	**Miles White** *Chairman and Chief Executive Officer*
9:45 - 10:30 a.m.	• Overview of Research-Based Pharmaceutical Company and Pipeline	**Richard Gonzalez** *Executive Vice President, Global Pharmaceuticals* *Future Chairman and CEO of Research-Based Pharmaceutical Company*
10:30 a.m.	• Q&A	**Miles White** **Richard Gonzalez** **Tom Freyman** *Executive Vice President, Finance and Chief Financial Officer* **John Leonard, M.D.,** *Senior Vice President, Pharmaceutical, R&D* **John Thomas** *Vice President, Investor Relations and Public Affairs* **Larry Peepo** *Divisional Vice President, Investor Relations*

Advancing Abbott:

Separating into Two Leading Companies:
Diversified Medical Products and Research-Based Pharmaceuticals

MILES D. WHITE

Chairman of the Board and CEO, Abbott

Abbott's Evolution
Strategic Actions Driving Shareholder Value

Strategic Action	Year	Rationale
Knoll acquisition	**2001**	• Expanded global footprint; bolstered pipeline with Humira
Hospira spin-off	**2004**	• Sharpened strategic focus, investment in higher-growth segments
Globalization of Nutritionals	**2006**	• Created international organization to enhance strategic focus
Guidant Vascular acquisition	**2006**	• Expanded vascular business, launched #1 DES (Xience)
Pharma pipeline prioritization	**2006**	• Narrowed discovery focus, emphasizing areas of greatest potential
Restructured Diagnostics	**2008**	• Repositioned for greater profitability
AMO acquisition	**2009**	• Entered demographically attractive vision care market
Solvay/Piramal acquisitions	**2010**	• Provided critical mass in emerging markets; #1 position in India
Creation of EPD	**2010**	• Provided focus to maximize portfolio of branded generics
Proprietary pharmaceutical pipeline augmentation	**2009-2011**	• Added to pharmaceutical pipeline with nearly a dozen new compounds (e.g. Facet, Neurocrine, Reata)

Next Step: Separation into Two Distinct, Leading Healthcare Companies

Strategic Rationale
Two Unique and Compelling Investment Identities

Divergent business models with distinct investment identities

Pharmaceuticals	Diversified Medical Products
• Sustainable portfolio of specialty brands • Significant potential for new products • Greater focus on developed world	• Balanced product portfolio and pipeline • Diverse payor base • Greater emerging markets presence

Two Independent, Publicly Traded Companies

	Abbott: Diversified Medical Products	New Pharmaceutical Company
Sales Mix		
Sales	~$22 Billion	Nearly $18 Billion
Chairman and CEO	Miles D. White	Richard A. Gonzalez
Key Brands	Similac, Xience V Everolimus Eluting Coronary Stent System, FreeStyle Blood Glucose Monitoring Systems, ARCHITECT, clarithromycin, TECNIS MULTIFOCAL IOL Diffractive Aspheric	HUMIRA adalimumab, LupronDepot (leuprolide acetate for depot suspension), SYNAGIS PALIVIZUMAB, KALETRA (lopinavir/ritonavir), CREON (pancrelipase) Delayed-Release Capsules, NIASPAN niacin Extended-Release Tablets

Abbott
A Promise for Life

Well Positioned as Two Independent Companies

Abbott: Diversified Medical Products	New Pharmaceutical Company
Strategic focus:	**Strategic focus**:
• Expanding geographically	• Continuing growth of leading brands
• Developing new technologies	• Advancing specialty-focused pharma pipeline
• Accelerating margins/cash flow	• Strong margins and robust cash flow

Strengths of Each Company

- ✓ Broad product portfolios, global scale and footprint
- ✓ Strong balance sheets
- ✓ Strong investment-grade credit ratings expected
- ✓ Significant, durable cash flow
- ✓ Each expected to pay dividend, when combined, will equal ABT dividend

The New Abbott:
A Leading Diversified Medical Products Company

Abbott
A Well-Balanced Portfolio

Established Pharma 25% of Sales	Medical Devices 27% of Sales
• Branded generics • 50% emerging markets	• Vascular Care • Vision Care • Diabetes Care

Diagnostics 20% of Sales	Global Nutritionals 28% of Sales
• Core Laboratory • Molecular • Point-of-Care	• Pediatric • Adult

Leveraging Abbott Brand Across Segments

Abbott
Broad Emerging Markets Exposure

Emerging market sales to approach 50% of sales by 2015



2011: Abbott Sales by Geography



2015: Abbott Sales by Geography

Emerging markets include all countries/regions excluding the developed world: U.S., Canada, W. Europe, Japan and Australia

Abbott
Delivering Top-Tier Performance

One of the largest and most attractive healthcare investments

- ✓ High-single-digit sales growth with well-stocked new product pipeline
- ✓ Gross and operating margin expansion across business segments
- ✓ Targeting sustainable double-digit ongoing earnings-per-share growth

Abbott Nutritionals
Leadership Positions



Global Nutritionals
- #1 or #2 in 20 countries
- Leadership for majority of categories
- 50 consumer brands; 140 countries

Pediatric Nutritionals
- #1 in the U.S.

Adult Nutritionals
- #1 in the U.S.
- #1 worldwide

Abbott
A Promise for Life

Abbott Nutritionals
Attractive Profile and Compelling Growth Opportunity

$40 Billion Market by 2015

- **Favorable Demographics**
- **Large and Growing Markets**
- **Significant Cash Flow Generation**
- **High Return on Invested Capital**

Well-positioned to capitalize on industry fundamentals through share gains, new products and line extensions

Abbott Nutritionals
U.S. Growth Drivers



Pediatric growth drivers

1. Infant formula share gains
2. Product line expansion

Adult growth drivers

1. Aging baby boomers
2. Market penetration
3. Expanding product line

Abbott
A Promise for Life

Abbott Nutritionals
International Growth Drivers

Abbott Nutrition International Sales Mix



International growth drivers

1. In-country expansion
2. Steady cadence of new product launches

Abbott Nutritional Sales Expectations

- 2011: >$2B emerging market sales
- 2014: ~$1B China-only sales

Abbott
A Promise for Life

Abbott Nutritionals
Sales Growth and Operating Margin Improvement

Share growth through superior execution, geographic expansion and new products

Generating sustainable double-digit sales growth

Improving both gross and operating margins

>700 basis point expansion in operating margin by 2015

Abbott Established Pharmaceuticals
Growing Leadership Positions

Established Pharmaceuticals
Global Sales Mix



Broad portfolio
- 500+ branded generic product portfolio
- Strong brand equity
- >50 percent of sales are self-pay

Large commercial footprint
- Large sales force; distribution network

Manufacturing expertise
- Driving efficiencies without compromising quality

Development pipeline
- Hundreds of new product launches

Abbott Established Pharmaceuticals
Reshaping Abbott for Emerging Market Growth



Strategic actions provide critical mass and right structure to become one of the largest branded generic pharmaceutical companies in emerging markets

Abbott Established Pharmaceuticals
New Business Model Poised to Deliver Growth

- ✓ Large sales and marketing organization focused on the brand
- ✓ 500+ diverse and growing product portfolio
- ✓ Quality manufacturing and nimble development organization
- ✓ Brand equity backed by the Abbott corporate identity

Scale, structure and single-minded focus on success

Abbott Diagnostics
Multiple Leadership Positions

Diagnostics
Global Sales Mix



Core Laboratory Diagnostics
- #1 in immunoassay
- #1 in blood screening
- >69,000 customers

Molecular Diagnostics
- Partner of choice in companion diagnostic tests
- Pioneering the rapidly developing bio-identification field with Plex-ID

Point of Care Diagnostics
- Market-leading bedside testing

Abbott
A Promise for Life

Abbott Diagnostics
Core Laboratory Diagnostics

Core Laboratory Diagnostics
Global Sales Mix



Key Growth Drivers

1. Share gains and in-country expansion
2. Next-generation platforms and systems

Abbott Diagnostics
Molecular Diagnostics

Global Sales
>$1BN in sales by 2015



Key growth drivers

1. *m*2000 share growth
2. Launch ~12 products in 5 years
3. Expand in companion diagnostics
4. Advance PLEX-ID system

Abbott Diagnostics
Point of Care Diagnostics

Global Sales
Doubling sales by 2015



Key growth drivers

1. Further penetrate bedside testing
2. International expansion

Abbott
A Promise for Life

Abbott Diagnostics
Historical Margin Improvement



Delivered 100 to 200 basis points of improvement in operating margin annually over the last 4 years

Abbott Diagnostics
Future Margin Expansion

Operating Margin
5-year CAGR: double-digits



Operating Margin Expectations

- >$1B in op margin by 2015
- >600 bps of expansion

Abbott
A Promise for Life

Abbott Medical Devices
Global Market Leadership

Global Sales Mix



Vascular Devices
- #1 drug-eluting stent brand
- #1 manufacturer of coronary stents
- #1 manufacturer of guidewires
- #1 carotid stent
- ~20 new products in pipeline

Vision Care
- Several category leadership positions

Diabetes Care
- Fastest growing in insulin-dependent patients in U.S.

Abbott Diabetes Care
Near-Term Growth Opportunities

Continued Focus on Insulin-Dependent Patients

Fastest growing U.S. BGM player in this segment

Successfully Launch New Products

Launched FreeStyle InsuLinx in EU in May

Continue to Improve Operating Margin

Improvement driven by patient mix and cost reductions

Abbott Vision Care
Share Gains and Geographic Expansion

Vision Care Growth by Category



Vision Care Growth by Geography



Growth Drivers

1. Share gains through product launches
2. Expand growth in international markets



Abbott
A Promise for Life

Abbott Vascular Care
Global Sales Growth



Abbott Vascular Care
Growth Shifting from U.S. to International

Global Coronary & Endovascular Market



Abbott Vascular Care
Coronary Leadership and Growth

Near-Term Growth Drivers

Drug-Eluting Stents

- Xience U.S. Share Leader
- Successful Xience Nano Launch
- Xience PRIME launch (U.S.) Coming Soon…

Core Coronary

- $800MM business
- Composed of BMS, guide wires, balloons
- TREK launch driving balloon share

Abbott Vascular Care
Endovascular Sales Outpacing Market Growth

Global Endovascular Market Growth



Endovascular Growth Drivers

1. >10 new product launches/indications
2. Share gains in emerging markets

Abbott
A Promise for Life

Abbott Vascular Care
Innovation Driving Growth Over Coming Years

Vascular pipeline select highlights

Drug-Eluting Stents
- ✓XIENCE NANO
- ✓XIENCE PRIME (EU)
- ✓ABSORB BVS (EU)
- XIENCE PRIME (U.S.)
- XIENCE PRIME-LL
- NEXT-GEN DES
- ABSORB BVS (U.S.)

Core Coronary
- ✓TREK
- ✓Mini-TREK
- BMW Elite Guide wire
- Next-gen guide wire

Structural Heart
- ✓MitraClip (EU)
- ✓MitraClip (Aus)
- MitraClip (U.S.)

Endovascular
- ✓XIENCE PRIME BTK
- ✓Armada 14 and 35
- ✓Acculink Carotid *(Expanded Indication)*
- Xpert Pro (EU)
- Armada 14 XT
- Omnilink Elite (U.S.)
- ABSORB BTK

Delivering ~20 new products over the next 5 years



✓ = recently received approval or launched

Abbott
A Promise for Life

Abbott Vascular Care
ABSORB BVS Technology

ABSORB is the next generation in treating coronary artery disease

Revolution 1
Balloon Angioplasty (PTCA)

1977

Revolution 2
Bare Metal Stents (BMS)

1988

Revolution 3
Drug-Eluting Stents (DES)

2001

Revolution 4
BVS Approved in EU

2011

Abbott Vascular Care
MitraClip for Mitral Regurgitation

Mitral Regurgitation Patient Population
Significantly Undertreated



Mitral Regurgitation
- Affects 8 million people
- Causes CHF, stroke, death

MitraClip Profile
- New treatment option for large unmet patient need
- Received EU approval in 2008
- Currently under FDA review
- Strong benefits seen in patients at high surgical risk and who have no other treatment alternatives



Abbott Vascular
Future Growth Drivers

Industry-leading pipeline delivering new products

Leadership across numerous segments

Emerging market growth opportunities

Endovascular expansion

✓Mid-to-high-single digit sales growth
✓Gross and operating margin improvement

Abbott: Diversified Medical Products Company

- Financially strong at ~$22B in sales with robust cash flow
- Well-balanced across businesses, geographies and payors
- Continued focus on opportunities in rapidly growing emerging markets
- High-single-digit sales growth; significant operating margin expansion

Expect to deliver sustainable double-digit ongoing earnings per share growth; among the fastest growing of medical products peers

New Research-Based Pharmaceutical Company: Business and Pipeline Overview

RICHARD A. GONZALEZ

Future Chairman and CEO,
Research-Based Pharmaceutical Company

New Pharmaceutical Company
Overview

Leading Proprietary Brands	**Leadership positions in immunology, HIV, cystic fibrosis, low testosterone, thyroid disease, among others**
Promising Pipeline	**Medicines that demonstrate strong clinical performance and economic value**
Strong Team	**Track record of outstanding execution**

KALETRA® (lopinavir/ritonavir)

norvir® (ritonavir)

ULTANE® sevoflurane

ZEMPLAR® (PARICALCITOL)

SYNAGIS® PALIVIZUMAB

Duodopa

LuproNDepot® (leuprolide acetate for depot suspension)

Abbott
A Promise for Life

New Pharmaceutical Company
Strategies for Growth

1. Grow Humira
2. Maximize current portfolio
3. Advance pipeline
4. Maximize emerging markets growth

Driven by strong commercial platform and productive R&D organization

Humira
Leading Global Biologic

- Best-in-class profile
  - Robust body of data
  - 6 approved indications; 6 currently in development
- Humira on track to become #1 biologic globally
  - #1 share position in 43 countries

Approved Indications	
1	Rheumatoid Arthritis
2	Psoriatic Arthritis
3	Ankylosing Spondylitis
4	Crohn's Disease
5	Psoriasis
6	Juvenile Idiopathic Arthritis

Expect Humira to be strong, sustainable global brand for years to come

Humira
Growth Strategies

1 Continue to expand the anti-TNF market	• Drive early diagnosis and faster cycling from conventional therapies • Increase penetration
2 Expand the HUMIRA patient base	• Launch new indications • Further penetrate in global markets such as Brazil, Japan, China, Russia
3 Improve patient adherence	• Continue to evolve best-in-class support programs

HUMIRA
adalimumab

Abbott
A Promise for Life

Humira
Expand the Anti-TNF Market



Humira
Expand Humira Patient Base – New Indication Rollout

	Current Indications	Future Indications
Rheumatology	✓ Rheumatoid Arthritis ✓ Ankylosing Spondylitis ✓ Psoriatic Arthritis ✓ Juvenile Idiopathic Arthritis	✓ Peripheral Spondyloarthropathies ✓ Axial Spondyloarthropathies
Gastroenterology	✓ Crohn's Disease	✓ Ulcerative Colitis ✓ Pediatric Crohn's Disease
Dermatology	✓ Psoriasis	✓ Hidradenitis Suppurativa
Ophthalmology		✓ Uveitis

New indications in development and other product enhancements underway

Humira
Potential Oral Entrants in Perspective

	Humira	JAK
Mechanism of Action	Well understood; 12+ yrs of data	Limited understanding; no long-term data
Safety	Well established	Limited understanding of safety profile
RA Efficacy	Well established	No incremental benefit over anti-TNF
Radiographic Inhibition	Well established; demonstrated ability to halt disease progression as early as 26 weeks and through 10 years	Failed primary radiographic endpoint at 5mg
Crohn's Disease Efficacy	Well established	Failed Phase II study
Psoriasis Efficacy	Class leading	Phase II: lower PASI scores at very high dose
Dosing/month	2 injections	60 pills (2x daily)

Physician and Patient Feedback	• Cautious use of JAK initially • Waiting for longer-term, real-world safety and durability outcomes • 2 pills per day not significant advantage over 2 injections per month

Biologics Market
Difficult to Penetrate; Established Therapies Well-Entrenched

U.S. Biologics Market*
IMS – TRx Prescription Share



Cimzia, Simponi, Actemra, Stelara, Rituxan, Kineret:
Total Share: 9.2%

Ex-U.S. Biologics Market**
Top 30 Ex-U.S. Markets – Patient Share



RoActemra, MabThera, Orencia, Simponi, Stelara, Cimzia:
Total Share: 11%

New Competitive Entrants Collectively Garnering Modest Share

** Source: IMS Marketshare data, July 2011*
*** Based on 3-month average patient share, top 30 ex-U.S. markets*

Potential Biosimilars in Perspective

- Humira has patent protection through early 2017 in U.S.; 2018 (Q1) in Europe
- Awaiting regulatory guidance on U.S. map to approval
  - Process will be far more extensive than small molecules
  - FDA moving carefully to ensure safety and efficacy equivalent to innovator
- Modest penetration in Europe from current biosimilars

	Potential Requirements
Clinical Data	• Likely to require animal and human clinical studies
Interchangeability	• Will not be directly interchangeable
Infrastructure/Costs to Generic Mfg.	• Significant investment in biologics infrastructure • Significant SG&A infrastructure, promotional investment

Generic erosion for biologics likely much slower and more limited than small molecules

Broad Portfolio of Specialty Therapies

- Focused on maximizing commercial portfolio; predominantly specialty products
- Planned realistically for maturing lipids
  - Humira represents durable growth vehicle, offsetting maturing lipids

Well-positioned for accelerating growth in 2015 and beyond

HUMIRA adalimumab

CREON (pancrelipase) Delayed-Release Capsules

LuproNDepot (leuprolide acetate for depot suspension)

SYNAGIS PALIVIZUMAB

ZEMPLAR (PARICALCITOL)

norvir (ritonavir)

Duodopa

KALETRA (lopinavir/ritonavir)

ULTANE sevoflurane

Abbott
A Promise for Life

New Pharmaceutical Company
Penetrating Emerging Markets

Key Emerging Markets

- China
- Brazil
- Russia
- Turkey
- Mexico
- Argentina
- Poland
- India
- South Korea
- Indonesia
- South Africa
- Vietnam

Emerging Market Sales



Abbott
A Promise for Life

Pharmaceutical Pipeline Snapshot

32 New molecular entities currently in human trials

15 Biologics currently in development (Discovery – Phase III)

>20 Compounds or indications currently in Phase II or Phase III

- **Numerous pipeline opportunities with breakthrough potential**
- **Goal to bring to market products that demonstrate strong clinical performance, patient benefit and economic value**

R&D Productivity



Pharmaceutical Pipeline Highlights



Abbott
A Promise for Life

Significant Opportunities

Humira – New Indications	Bardoxolone	HCV Combo	Daclizumab
New indications represent >$1BN incremental peak-sales	First-in-class compound; potential to dramatically change treatment landscape	Triple-combo has potential to shorten and simplify treatment; increase cure rates	Potential for high efficacy with manageable safety

Significant peak-year sales potential

Global Epidemic of Chronic Kidney Disease (CKD)

CKD currently affects 50 million adults in U.S. and Europe

- Risk factors include hypertension, diabetes, obesity and age
- Incidence of hypertension and diabetes expected to increase ~60 percent by 2025

Chronic Kidney Disease
Bardoxolone

Disease Overview

- Current treatments (non-specific) only modestly slow progression
- Patients ultimately progress to end-stage disease/dialysis
- Significant cost to healthcare systems worldwide
  - Annual cost of treatment of average dialysis patient >$75K
- Significant quality-of-life implications
- To date, no treatments shown to reverse progression

Bardoxolone Highlights

- Phase III program underway
- Oral, first-in-class anti-inflammatory: Nrf2 activator
  - Novel mechanism of action
- Improves estimated glomerular filtration rate (eGFR)
- Improves kidney's ability to filter and remove waste from the body
- First-and-only treatment shown to reverse disease progression

Bardoxolone
Registrational Trial Results: Published in *NEJM*

Phase 2 Bardoxolone Registrational Trial (BEAM Study)



Source: *New England Journal of Medicine*

Key finding: Significant and sustained improvement in kidney function as measured by eGFR, indicating potential for preventing or postponing dialysis or transplant

Bardoxolone
Phase III Study: BEACON

- 1,600 patients at 300 sites worldwide
- Stage 4 CKD and type 2 diabetes patients
- Bardoxolone or placebo, plus standard of care (ACE/ARB)
- Primary endpoint: time to first event of composite endpoint consisting of ESRD or CV death
- Event-driven study, expected to take approximately two years to complete
- Study enrolling ahead of forecast
- Potential commercialization in 2014

Bardoxolone – Abbott Regions

Territory Key

- Abbott
- Reata
- Kyowa



Development and commercialization rights outside of the U.S., excluding certain Asian markets

Abbott
A Promise for Life

Chronic Kidney Disease
Atrasentan

Atrasentan Highlights

- Abbott discovered compound
- Selective endothelin-A receptor antagonist
  - Blocks the effect of a protein that constricts blood vessels and raises blood pressure, impacting kidney function
- Phase II data showed reduction of albuminuria (protein in urine)
- Phase IIB study currently underway
- Pending data, potential to start Phase III program in 2012
- Complementary asset in CKD portfolio
  - Potential to treat patients earlier in disease progression
- Potential commercial entry in 2015

Pharmaceutical Pipeline
Neuroscience and Pain Management

Preclinical	Phase I	Phase II	Phase III / Filed
ABT-363	ABT-436	**ABT-126 (α7 NNR)** Alzheimer's Disease	**Daclizumab (CD25)** Multiple Sclerosis
ABT-957	ABT-354	**ABT-126 (α7 NNR)** Cognitive Deficits of Schizophrenia (CDS)	**Duodopa - US** Parkinson's Disease
5-HT6, Calpain, D3, GlyT1, RGMa, S1P5	ABT-560	**ABT-639 (Cav3.2)** Pain	
ABT-443	ABT-110	**ABT-652 (H3)** Pain	
CB2, Cav, TRPV1	ABT-272		
	ABT-521		

Neuroscience

Pain

Abbott
A Promise for Life

Neuroscience/Pain
Significant Global Prevalence

Multiple Sclerosis

Affects ~one million people worldwide

Parkinson's Disease

Affects ~five million people worldwide

Cognitive Deficits of Schizophrenia

Affects ~one percent of world population

Alzheimer's Disease

Affects 18 million people worldwide; expected to double by 2015

Pain

Affects >70 million people in the U.S.; number one reason people visit the doctor

Neuroscience
Multiple Sclerosis

Disease Overview	
	• Disorder in which immune system attacks the myelin, which protects nerve fibers • Most common progressive and disabling neurological condition in young adults • Average age of onset ~30 years • Motor disability typically worsens over the course of years • $11BN market growing to more than $14BN by 2020



Neuroscience
Multiple Sclerosis: Daclizumab

Daclizumab Highlights

- In development for relapsing remitting MS (RRMS)
  - Most common form of the disease
  - 85% of patients initially diagnosed with RRMS
- Current therapies have either marginal efficacy with nuisance side effects or high efficacy and serious, unpredictable side effects (i.e. PML)
  - Daclizumab offers potential to deliver right balance of high efficacy, manageable safety

Phase IIB data promising: potential for annual relapse rate similar to other next-generation therapies

Daclizumab
Phase IIB SELECT Results

Key findings

- 54% relative reduction in relapse rate
- 57% reduction in risk of disability progression (tertiary endpoint)
- Manageable safety

Next Steps

- Phase III study currently underway (DECIDE)
- Potential U.S. filing in 2014
- Commercialization starting in 2015

First Pivotal Trial: "SELECT"
Annualized Relapse Rate (ARR) at 1 year



DECIDE
Investigating a new pathway in MS

Abbott
A Promise for Life

Neuroscience
Parkinson's Disease

Disease Overview	• Chronic, progressive brain disorder resulting from loss of dopamine-producing brain cells • Leads to tremor, muscle rigidity, slowness of movement and difficulty with balance • Affects ~five million people worldwide
Abbott Program Highlights	• **Duodopa** currently in Phase III (U.S.) • Infused directly into small intestine via a portable pump • Currently on market in most European countries • Expect to report U.S. pivotal data and submit U.S. regulatory application in 2012

Neuroscience
Additional Research Highlights

Evaluating compounds targeting Alzheimer's disease, cognitive deficits of schizophrenia (CDS), anxiety, depression and pain

Therapeutic Approaches

- Researching a variety of mechanisms, including:
  - **α7 NNR**: Potential to alleviate cognitive deficits associated with a variety of diseases
  - **5-HT_6** : Effective in memory/cognition models related to attention and spatial and working memory
  - **V1b:** Shows promise as novel mechanism for treatment of depression and anxiety
- Researching non-opioid agents for relief across a broad spectrum of pain states:
  - Postoperative
  - Back pain
  - Cancer pain
  - Osteoarthritis pain

Pharmaceutical Pipeline
Immunology

Preclinical	Phase I	Phase II	Phase III / Filed
ABT-362	**ABT-308 (IL-13)**	**HUMIRA (anti-TNF)** Hidradenitis suppurativa	**HUMIRA (anti-TNF)** ulcerative colitis
ABT-494	**ABT-413 (S1P1,5)**	**BT-061 (CD4)** Rheumatoid Arthritis	**HUMIRA (anti-TNF)** Spondyloarthropathies
ABT-122 – DVD-Ig	By year-end '11	**BT-061 (CD4)** Psoriasis	**HUMIRA (anti-TNF)** Uveitis
ABT-981 – DVD-Ig	By year-end '11		
MMP-13			
SYK			

DVD-Ig
Uniting Two Antibodies in Single Agent

Program Overview

- Proprietary platform technology enables uniting of two antibodies in a single agent
- Multiple potential indications, including immunology, cancer, pain

Next Steps

- On track to start human trials of first pairs by year-end
  - ABT-122: anti-TNF/IL-17 (RA)
  - ABT-981: IL-1 α/β (osteoarthritis)



Pharmaceutical Pipeline
Oncology

Preclinical	Phase I	Phase II	Phase III / Filed
ABT-487	**ABT-199**	**Linifanib (kinase)** NSCLC	**Elotuzumab (CS-1)** Multiple Myeloma
ABT-731	**ABT-348**	**Navitoclax (bcl-2)** Lymphomas	**Linifanib (Kinase)** Hepatocellular Cancer
ABT-414	**ABT-767**	**Navitoclax (bcl-2)** Solid tumors	
	ABT-806	**Navitoclax (bcl-2)** SCLC	
	TRU-016	**Navitoclax (bcl-2)** NSCLC	
	Volociximab	**Navitoclax (bcl-2)** Other cancers	
	ABT-700	**Veliparib (PARP)** Ovarian cancer	
		Veliparib (PARP) Colorectal cancer	
		Veliparib (PARP) Breast cancer	
		Veliparib (PARP) Solid tumors	
		Veliparib (PARP) Lymphomas	
		Veliparib (PARP) Other cancers	

Oncology Partnerships

Oncology
Program Highlights

Abbott Program Highlights	
	Elotuzumab (CS1) (Partner: Bristol-Myers Squibb) • Phase II data showed high response rates • Currently in Phase III for multiple myeloma **Linifanib** (Multi-targeted kinase inhibitor) • Cuts off blood supply to tumor to stop disease progression • In development for several cancer types **Veliparib** (PARP-inhibitor) • Phase IIB in breast to begin 2H11 • Also being evaluated in brain metastases, non-small-cell lung cancer and colorectal cancer **Bcl inhibitors** (Partner: Genentech/Roche) • Navitoclax (Bcl inhibitor): Phase II for CLL, solid tumors • ABT-199 (Bcl-2 selective inhibitor); currently in Phase I for hematologic malignancies

Women's Health
Endometriosis and Uterine Fibroids

Disease Overview	• 17MM women with endometriosis • >1.5MM seek treatment/yr vs. 55K treated due to side effects • 19MM women with uterine fibroids • Side-effect profile for endometriosis treatments include hot flashes, bone density changes; surgery only option for fibroids • Opportunity for treatments with high efficacy *and* better safety
Elagolix Highlights	**Elagolix** (Partner: Neurocrine) • Compound uniquely provides partial estrogen suppression • On track to start Phase III for endometriosis • Recently started Phase II uterine fibroids; opportunity to be first and only treatment

Virology
Hepatitis C Virus

Disease Overview	• 180MM people infected worldwide – More than 4MM newly diagnosed per year globally • 80% of infections chronic, leading to long-term complications • Heterogeneous disease; number of genotypes and subtypes • $3BN market growing to $12BN by 2015 • New therapies require interferon; difficult for many patients to tolerate – Still long and complex treatment regimens • Treatment landscape continuing to evolve – Opportunity to offer vast improvement over current therapies

Hepatitis C Virus
Strategic Approach

Broad HCV program: Protease, Polymerase and NS5A inhibitors in development

1. High cure rates in broadest range of patients
2. Significantly shorten and simplify course of therapy
3. Interferon-free

Opportunity to dramatically change treatment landscape

Hepatitis C Virus
Interferon-Free Combination Program

ABT-450 Protease Inhibitor (Partner: Enanta)	ABT-267 NS5A Inhibitor	ABT-072 and ABT-333 Non Nucleoside Polymerase Inhibitors
• High potency • Low resistance • Good tolerability • QD dosing	• Significant antiviral activity • QD dosing • No safety signals identified	• Additive antiviral activity to SOC • Well-tolerated • Complementary assets

- Phase IIB program recently initiated
- First time evaluating all three classes in combination
- Evaluating various permutations of three MOA

Hepatitis C Virus
PILOT/CO-PILOT Studies – Interim Results

- PILOT AND CO-PILOT interim results are unprecedented and very promising
- Others in field have shown interferon-free cure is possible, but restricted to easier to treat genotype, and with 24 weeks of therapy
- Interim results from PILOT and CO-PILOT demonstrate cure can be achieved in broad range of patients, with shorter course of therapy
  - Very high cure rates in a broad range genotype 1, interferon-naïve patients
  - Significantly shorter and simpler treatment: 12 weeks
  - Interferon-free

Additional data presented next year will shed further light on our advancing program

Pharmaceutical – Select Pipeline Highlights

Compound	Indication	2011	2012	2013	2014	2015	2016
Humira	Ulcerative Colitis	★					
	Pediatric Crohn's		★				
	SpA Peripheral			★			
	SpA Axial			★			
	Uveitis				★		
	Hidradenitis Suppurativa					★	
Duodopa	Advanced Parkinson's	PIII data		★			
Linifanib	Hepatocellular Carcinoma		PIII data (HCC)	★			
Bardoxolone	Chronic Kidney Disease	PIII Start		BEACON Data	★		
Daclizumab	Relapsing Remitting MS	SELECT Data (PIIb)			DECIDE Data	★	
HCV Combo	HCV	PIIb Start	PIIb Data	PIII Start	PIII Data	★	
Elotuzumab	Multiple Myeloma	PIII Start				★	
Elagolix	Endometriosis	Finalize PIII Program				PIII data	★
	Uterine Fibroids	PII Start			PIII Start		

Projected Data Availability Planned Regulatory Filing ★ Potential Approval

Abbott
A Promise for Life

Summary

- Compelling opportunity to create new, independent pharmaceutical company
  - Distinct investment opportunity for shareholders
  - Greater visibility enables investors to clearly value new company
- Well-positioned to succeed as an independent company
  - Portfolio of leading brands, such as Humira, which will drive strong, sustainable earnings growth and cash flow
  - Advancing pipeline to fuel future growth
  - Strong track record of performance and execution

Q&A

Advancing Abbott's Long-term Strategy

Separating into Two Leading Companies in Diversified Medical Products and Research-Based Pharmaceuticals

October 21, 2011

Abbott
A Promise for Life